|
1
|
Price KA and Cohen EE: Current treatment
options for metastatic head and neck cancer. Curr Treat Options
Oncol. 13:35–46. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vermorken JB and Specenier P: Optimal
treatment for recurrent/metastatic head and neck cancer. Ann Oncol.
21 Suppl:vii252–vii261. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guigay J, Fayette J, Dillies AF, Sire C,
Kerger JN, Tennevet I, Machiels JP, Zanetta S, Pointreau Y, Bozec
Le Moal L, et al: Cetuximab, docetaxel, and cisplatin as first-line
treatment in patients with recurrent or metastatic head and neck
squamous cell carcinoma: A multicenter, phase II GORTEC study. Ann
Oncol. 26:1941–1947. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tahara M, Kiyota N, Yokota T, Hasegawa Y,
Muro K, Takahashi S, Onoe T, Homma A, Taguchi J, Suzuki M, et al:
Phase II trial of combination treatment with paclitaxel,
carboplatin and cetuximab (PCE) as first-line treatment in patients
with recurrent and/or metastatic squamous cell carcinoma of the
head and neck (CSPOR-HN02). Ann Oncol. 29:1004–1009. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harrington KJ, Ferris RL, Blumenschein G
Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE,
Worden F, et al: Nivolumab versus standard, single-agent therapy of
investigator's choice in recurrent or metastatic squamous cell
carcinoma of the head and neck (CheckMate 141): Health-related
quality-of-life results from a randomised, phase 3 trial. Lancet
Oncol. 18:1104–1115. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Saada-Bouzid E, Defaucheux C, Karabajakian
A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J,
Loirat D, et al: Hyperprogression during anti-PD-1/PD-L1 therapy in
patients with recurrent and/or metastatic head and neck squamous
cell carcinoma. Ann Oncol. 28:1605–1611. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Towle MJ, Salvato KA, Budrow J, Wels BF,
Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, et
al: In vitro and in vivo anticancer activities of synthetic
macrocyclic ketone analogues of halichondrin B. Cancer Res.
61:1013–1021. 2001.PubMed/NCBI
|
|
10
|
Jordan MA, Kamath K, Manna T, Okouneva T,
Miller HP, Davis C, Littlefield BA and Wilson L: The primary
antimitotic mechanism of action of the synthetic halichondrin E7389
is suppression of microtubule growth. Mol Cancer Ther. 4:1086–1095.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okouneva T, Azarenko O, Wilson L,
Littlefield BA and Jordan MA: Inhibition of centromere dynamics by
eribulin (E7389) during mitotic metaphase. Mol Cancer Ther.
7:2003–2011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smith JA, Wilson L, Azarenko O, Zhu X,
Lewis BM, Littlefield BA and Jordan MA: Eribulin binds at
microtubule ends to a single site on tubulin to suppress dynamic
instability. Biochemistry. 49:1331–1337. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuznetsov G, Towle MJ, Cheng H, Kawamura
T, TenDyke K, Liu D, Kishi Y, Yu MJ and Littlefield BA: Induction
of morphological and biochemical apoptosis following prolonged
mitotic blockage by halichondrin B macrocyclic ketone analog E7389.
Cancer Res. 64:5760–5766. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Towle MJ, Salvato KA, Wels BF, Aalfs KK,
Zheng W, Seletsky BM, Zhu X, Lewis BM, Kishi Y, Yu MJ and
Littlefield BA: Eribulin induces irreversible mitotic blockade:
Implications of cell-based pharmacodynamics for in vivo efficacy
under intermittent dosing conditions. Cancer Res. 71:496–505. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kitahara H, Hirai M, Kato K, Bou-Gharios
G, Nakamura H and Kawashiri S: Eribulin sensitizes oral squamous
cell carcinoma cells to cetuximab via induction of
mesenchymal-to-epithelial transition. Oncol Rep. 36:3139–3144.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaufman PA, Awada A, Twelves C, Yelle L,
Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE and Cortes J: Phase
III open-label randomized study of eribulin mesylate versus
capecitabine in patients with locally advanced or metastatic breast
cancer previously treated with an anthracycline and a taxane. J
Clin Oncol. 33:594–601. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yokoi T, Homma H and Odajima T:
Establishment and characterization of OSC-19 cell line in serum and
protein free culture. Tumor Res. 24:1–17. 1988.
|
|
18
|
Kawashiri S, Noguchi N, Tanaka A, Nakaya
H, Kato K and Yamamoto E: Inhibitory effect of neoadjuvant
chemotherapy on metastasis of oral squamous cell carcinoma in a
mouse model. Oral Oncol. 45:794–797. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yokoi T, Hirata S, Nishimura F, Miyakawa
A, Odajima T and Kohama G: Some properties of a newly established
human cell line derived from an oral squamous carcinoma. Tumor Res.
25:93–91-93. 1990.
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jordan MA and Wilson L: Microtubules as a
target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bai R, Nguyen TL, Burnett JC, Atasoylu O,
Munro MH, Pettit GR, Smith AB III, Gussio R and Hamel E:
Interactions of halichondrin B and eribulin with tubulin. J Chem
Inf Model. 51:1393–1404. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nogales E, Wolf SG, Khan IA, Luduena RF
and Downing KH: Structure of tubulin at 6.5 A and location of the
taxol-binding site. Nature. 375:424–427. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bai RL, Pettit GR and Hamel E: Binding of
dolastatin 10 to tubulin at a distinct site for peptide antimitotic
agents near the exchangeable nucleotide and vinca alkaloid sites. J
Biol Chem. 265:17141–17149. 1990.PubMed/NCBI
|
|
25
|
Dezső Z, Oestreicher J, Weaver A, Santiago
S, Agoulnik S, Chow J, Oda Y and Funahashi Y: Gene expression
profiling reveals epithelial mesenchymal transition (EMT) genes can
selectively differentiate eribulin sensitive breast cancer cells.
PLoS One. 9:e1061312014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mendelsohn W: The significance of abnormal
mitosis in the development of malignancy. Am J Cancer. 24:626–636.
1935.
|
|
27
|
Miki S, Imamichi S, Fujimori H, Tomiyama
A, Fujimoto K, Satomi K, Matsushita Y, Matsuzaki S, Takahashi M,
Ishikawa E, et al: Concomitant administration of radiation with
eribulin improves the survival of mice harboring intracerebral
glioblastoma. Cancer Sci. 109:2275–2285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Swami U, Chaudhary I, Ghalib MH and Goel
S: Eribulin-A review of preclinical and clinical studies. Crit Rev
Oncol Hematol. 81:163–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wilson L, Lopus M, Miller HP, Azarenko O,
Riffle S, Smith JA and Jordan MA: Effects of eribulin on
microtubule binding and dynamic instability are strengthened in the
absence of the beta III tubulin isotype. Biochemistry.
54:6482–6489. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Person F, Wilczak W, Hube-Magg C,
Burdelski C, Möller-Koop C, Simon R, Noriega M, Sauter G, Steurer
S, Burdak-Rothkamm S and Jacobsen F: Prevalence of beta III-tubulin
(TUBB3) expression in human normal tissues and cancers. Tumour
Biol. 39:10104283177121662017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koh Y, Jang B, Han SW, Kim TM, Oh DY, Lee
SH, Kang CH, Kim DW, Im SA, Chung DH, et al: Expression of class
III beta-tubulin correlates with unfavorable survival outcome in
patients with resected non-small cell lung cancer. J Thorac Oncol.
5:320–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lebok P, Ozturk M, Heilenkotter U,
Jaenicke F, Müller V, Paluchowski P, Geist S, Wilke C, Burandt E,
Lebeau A, et al: High levels of class III beta-tubulin expression
are associated with aggressive tumor features in breast cancer.
Oncol Lett. 11:1987–1994. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hinsch A, Chaker A, Burdelski C, Koop C,
Tsourlakis MC, Steurer S, Rink M, Eichenauer TS, Wilczak W, Wittmer
C, et al: βIII-tubulin overexpression is linked to aggressive tumor
features and genetic instability in urinary bladder cancer. Hum
Pathol. 61:210–220. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Loeser H, Schallenberg S, von Winterfeld
M, Tharun L, Alakus H, Hölscher A, Bollschweiler E, Buettner R,
Zander T and Quaas A: High protein and mRNA expression levels of
TUBB3 (class III ss-tubulin) are associated with aggressive tumor
features in esophageal adenocarcinomas. Oncotarget.
8:115179–115189. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nienstedt JC, Grobe A, Clauditz T, Simon
R, Muenscher A, Knecht R, Sauter G, Moebius C, Blessmann M, Heiland
M and Pflug C: High-level betaIII-tubulin overexpression occurs in
most head and neck cancers but is unrelated to clinical outcome. J
Oral Pathol Med. 46:986–990. 2017.PubMed/NCBI
|
|
36
|
Bachurski CJ, Theodorakis NG, Coulson RM
and Cleveland DW: An amino-terminal tetrapeptide specifies
cotranslational degradation of beta-tubulin but not alpha-tubulin
mRNAs. Mol Cell Biol. 14:4076–4086. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Stargell LA, Heruth DP, Gaertig J and
Gorovsky MA: Drugs affecting microtubule dynamics increase
alpha-tubulin mRNA accumulation via transcription in Tetrahymena
thermophila. Mol Cell Biol. 12:1443–1450. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arnold SM, Moon J, Williamson SK, Atkins
JN, Ou SH, LeBlanc M and Urba SG: Phase II evaluation of eribulin
mesylate (E7389, NSC 707389) in patients with metastatic or
recurrent squamous cell carcinoma of the head and neck: Southwest
Oncology Group trial S0618. Invest New Drugs. 29:352–359. 2011.
View Article : Google Scholar : PubMed/NCBI
|
